^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Small Intestinal Carcinoma

1d
Conversion surgery after pembrolizumab for initially unresectable MSI-H small bowel adenocarcinoma: a case report and brief analysis. (PubMed, Immunotherapy)
Initial chemotherapy with FOLFOX (oxaliplatin, fluorouracil, and folinic acid) was initiated; however, a microsatellite instability-high (MSI-H) status was identified, and the treatment was promptly switched to pembrolizumab. Additionally, a brief meta-analysis of 10 studies comprising 72 patients with MSI-H/mismatch repair-deficient SBA revealed an objective response rate to immune checkpoint inhibitors of 65.3%. This case highlights the potential of pembrolizumab for the curative resection of an initially unresectable MSI-H SBA.
Journal • MSI-H
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
3d
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy (clinicaltrials.gov)
P2, N=78, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
Trial completion date • Trial primary completion date • Head-to-Head
4d
A Solitary Duodenal Metastasis from Transverse Colon Cancer Detected Six Years after Curative Resection: A Case Report. (PubMed, Surg Case Rep)
Although extremely rare, the possibility of isolated duodenal recurrence after surgery for colon cancer exists. With a brief review of the literature, we report here a rare recurrence case of transverse colon cancer which was discovered at 6 years postoperatively and resulted in curative resection.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
8d
Remission of metastatic duodenal cancer after treatment with BRAF inhibitor (PubMed, Ugeskr Laeger)
Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the importance of molecular profiling in rare cancers. Further research is needed on the effect and safety of targeted therapy for small bowel adenocarcinoma.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)
10d
Small Bowel Gastrointestinal Stromal Tumors: A 15-Year Cohort Study Focusing on Jejuno-Ileal Site-Specific Outcomes and Prognostic Factors. (PubMed, Cancers (Basel))
Extended, risk-adapted surveillance may be reasonable for small-bowel GISTs, and it may be beneficial to incorporate Ki-67 (≥5%) into site-based risk stratification. These observations remain hypothesis-generating and require validation in larger, multicenter cohorts and prospective studies.
Journal
|
NF1 (Neurofibromin 1)
16d
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy (clinicaltrials.gov)
P=N/A, N=90, Recruiting, Minia University | Not yet recruiting --> Recruiting
Enrollment open
18d
Beyond the Watershed: Chronic Ischemic Colitis Masking Underlying Small Bowel Non-Hodgkin Lymphoma. (PubMed, Cureus)
She required intensive care with vasopressors and mechanical ventilation and was treated for cytomegalovirus viremia with intravenous ganciclovir followed by valganciclovir. Primary intestinal lymphoma can mimic IC through obstruction and microvascular compromise. Early recognition of atypical right-sided IC is essential, as prompt surgery and biopsy can identify underlying malignancy and guide timely oncologic management.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
Valcyte (valganciclovir)
21d
New P2 trial • Tumor mutational burden
|
BRAF (B-raf proto-oncogene)
|
Padcev (enfortumab vedotin-ejfv)
28d
New trial
29d
Inflammatory myofibroblastic tumor on second portion of duodenum: a case report. (PubMed, Korean J Clin Oncol)
In the present manuscript, we provide a subsequent long-term follow-up report of the same patient, offering an extended 88-month postoperative course and additional radiologic and pathologic details not included in the earlier publication. This follow-up report highlights the long-term benign behavior of the tumor despite positive surgical margins and anaplastic lymphoma kinase (ALK)-negative immunohistochemistry, contributing meaningful information to the scarce literature on adult duodenal IMTs.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK negative
1m
The Vascular Density/Angiogenesis Marker CD31/PECAM1 does not Correlate with Overall Survival in Neuroendocrine Tumors. (PubMed, J Gastrointest Cancer)
NEN tumors are highly vascularized and consistently positive for CD31. Despite reports that CD31/PACAM1 is important to cell adhesion and tumor phenotype, there was no identifiable measurable impact of high CD31 levels on NEN. Nor was there a prognostic clinical value for CD31 staining quantification.
Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
1m
Review of Familial Adenomatous Polyposis: Current Understanding and Clinical Management. (PubMed, JCO Oncol Pract)
Management of FAP is complex, and patients require frequent and lifelong surveillance. This review will discuss the current understanding and clinical management of FAP as well as innovations and challenges in clinical practice.
Review • Journal
|
APC (APC Regulator Of WNT Signaling Pathway) • FAP (Fibroblast activation protein, alpha)